Company Analysis
Sign in

Telix Pharmaceuticals Limited (TLX)

Nasdaq: TLX · Pharmaceutical Preparations · North Melbourne, AU · filing with the SEC since 2024
Full chart Alerts Compare
Grade6.6
◀ Past 7.7● Present 6.8▶ Future 5.2
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

The grade of Telix Pharmaceuticals Limited

Nine metrics read from its own filings, by tense
Headline grade
6.6/10
◀ Past7.730% of the headline
● Present6.840% of the headline
▶ Future5.230% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

7.7/1030% of the headline grade · 3 of 3 filed

Surviving crises

as filed
8.2/10

Has it survived what it has been through?

No warning events in its filings since 2024.

weight 33% of this tense · 82nd percentile among 497 sector filers · read for itself

From the record

Telix Pharmaceuticals Limited's filings since 2024 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed
8.7/10

What has it actually done, year after year?

+55.3% a year over 3 filed years; profitable in 2 of 3.

weight 45% of this tense · 87th percentile among 323 sector filers · read for its customers

From the record

Telix Pharmaceuticals Limited's 3 filed years say what it did: revenue went from $333 million in fiscal 2023 to $804 million in fiscal 2025, up 55.3% a year; it rose in 2 of 2 years; it never fell from a peak; net income was positive in 2 of 3 of those years (its annual reports).

What it rests on

  • revenue growth over the filed span55.3%top 22% of its family
  • the share of years revenue rosetop 8% of its family
  • the share of filed years with a profittop 12% of its family
  • the deepest fall from a revenue peak0.0%top 10% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

as filed
4.9/10

How has it treated the people who own it?

Share count grew 2.8% a year. 0% of cash flow returned. Insiders: 0 sales, 3 purchases.

weight 22% of this tense · 49th percentile among 80 sector filers · read for its shareholders

From the record

Over the 3 fiscal years to 2025-12-31, Telix Pharmaceuticals Limited's diluted share count grew about 2.8% a year, and dividends and buybacks returned about 0% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 0 sales and 3 purchases of their own stock on the open market in the year to 2026-09-30, buying about $1 million (their Form 4 filings).

What it rests on

  • the share count over the yearstop 22% of its family
  • cash returned against operating cash flowbottom 20% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

● Present

What are they doing right now?

6.8/1040% of the headline grade · 2 of 3 filed, 1 estimated

Financial health

as filed
6.8/10

Is it financially healthy right now?

ROE -2%: lost 2¢ per shareholder dollar. Leverage 64%: owes 64¢ per asset dollar.

weight 45% of this tense · 68th percentile among 473 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, Telix Pharmaceuticals Limited lost about 2 cents for every dollar of shareholders' money, and gross profitability: its products earned about 37 cents per dollar of everything the company owns. Leverage: it owed about 64 cents per dollar of assets, and net share issuance: its share count shrank 2.1% over the year (the filed statements).

What it rests on

  • what it owes per dollar of assetsbottom 24% of its family
  • return on equitytop 17% of its family
  • gross profit against assetstop 32% of its family
  • the share count against the year beforetop 4% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed
8.0/10

How strong is its position in its industry?

top 20% of 315 in its family; net margin -0.9%.

weight 33% of this tense · 80th percentile among 315 sector filers · read for its customers

From the record

Telix Pharmaceuticals Limited's standing among 315 graded names in its industry family: revenue of $804 million in fiscal 2025 ranks in the top 14% by size; a net margin of -0.9% ranks in the top 25%; revenue growth of 55.3% a year over the last 2 filed years ranks in the top 23% (its annual reports).

What it rests on

  • revenue against the family$804Mtop 14% of its family
  • net margin-0.9%top 25% of its family
  • three-year revenue growth55.3%top 23% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

SI estimate
5.0/10

What are the people in charge doing?

SI estimate 5.0/10, confidence 20 of 100 (family median).

weight 22% of this tense · 50th percentile among 371 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
It files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-03-18 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 8 months and cannot see past it; a floor under five years is not read as years in charge, so the desk assumes the typical reading of its industry family, the median of 371 members with one.
What the record cannot read
It files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-03-18 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 8 months and cannot see past it; a floor under five years is not read as years in charge.
How it was reasoned
family median, 371 readings behind it.
Confidence
20 of 100
What would change it
Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Telix Pharmaceuticals Limited's leadership is put at 5.0 of 10 with a confidence of 20 of 100, because it files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-03-18 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 8 months and cannot see past it; a floor under five years is not read as years in charge, so the desk assumes the typical reading of its industry family, the median of 371 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

▶ Future

What are they set up to do next?

5.2/1030% of the headline grade · 2 of 3 filed, 1 estimated

Room to expand

as filed
3.3/10

How much room does it have to grow?

bottom 32% of 273 in its family for room to expand.

weight 45% of this tense · 32nd percentile among 273 sector filers · read for itself

From the record

Telix Pharmaceuticals Limited's room to grow, from the newest filed statements (fiscal 2025): cash of $142 million against debt of $405 million leaves -22.6% of its assets as net cash, bottom 7% of its family; cash from operations less capital spending is -5.3% of revenue (top 32%); a gross margin of 53.1% (bottom 27%); research spending of 21.3% of revenue (bottom 27%) (its annual report).

What it rests on

  • cash less debt against assets-22.6%bottom 7% of its family
  • cash from operations less capital spending against revenue-5.3%top 32% of its family
  • gross margin53.1%bottom 27% of its family
  • research spending against revenue21.3%bottom 27% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed
7.9/10

What could actually drive growth from here?

top 21% of 306 in its family for growth drivers.

weight 33% of this tense · 79th percentile among 306 sector filers · read for its customers

From the record

Telix Pharmaceuticals Limited's growth drivers, from the filed years to fiscal 2025: revenue grew 55.3% a year over the last three filed years against 55.3% over all 3, speeding up (top 40% of its family); the newest year grew 55.7% (top 23%); research spending grew 41.6% a year (top 11%); capital spending grew 101.7% a year (top 9%) (its annual reports). Telix Pharmaceuticals Limited tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

  • three-year growth against the whole span+0.0 points a yeartop 40% of its family
  • the newest year's revenue growth55.7%top 23% of its family
  • three-year growth of research spending41.6%top 11% of its family
  • three-year growth of capital spending101.7%top 9% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

SI estimate
5.3/10

Did its newest year beat what its own record pointed to?

SI estimate 5.3/10, confidence 20 of 100 (family median).

weight 22% of this tense · 50th percentile among 234 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change, so the desk assumes the typical reading of its industry family, the median of 234 members with one.
What the record cannot read
The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change.
How it was reasoned
family median, 234 readings behind it.
Confidence
20 of 100
What would change it
Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Telix Pharmaceuticals Limited's expectations vs reality is put at 5.3 of 10 with a confidence of 20 of 100, because the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change, so the desk assumes the typical reading of its industry family, the median of 234 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton TLX · research, not advice